A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy.

Publication year 2012

Published in British Journal of Ophthalmology

Authors R.J. Van Geest, S.Y. Lesnik-Oberstein, H.S. Tan, M. Mura, R. Goldschmeding, C.J. Van Noorden, I. Klaassen, R.O. Schlingemann

Support our work!

The Friends Foundation facilitates groundbreaking brain research. You can help us with that.